Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan 23:75:128262.
doi: 10.1016/j.vaccine.2026.128262. Online ahead of print.

Estimates of SARS-CoV-2 vaccine effectiveness against COVID-19-associated hospitalisation in paediatric patients in Hong Kong during two successive SARS-CoV-2 epidemic waves dominated by the Omicron variant: A test-negative design study

Affiliations

Estimates of SARS-CoV-2 vaccine effectiveness against COVID-19-associated hospitalisation in paediatric patients in Hong Kong during two successive SARS-CoV-2 epidemic waves dominated by the Omicron variant: A test-negative design study

George N Okoli et al. Vaccine. .

Abstract

Background: We assessed the effectiveness of SARS-CoV-2 vaccines against COVID-19-associated hospitalisation in paediatric patients in Hong Kong.

Methods: We conducted a test-negative design study in hospitalised children 1-17 years old admitted with recent-onset (≤5 days) acute respiratory illness in two large public hospitals in Hong Kong during successive SARS-CoV-2 epidemic waves between April 2022 and February 2024 dominated by the Omicron variant. We defined having been vaccinated as receipt of ≥1 SARS-CoV-2 vaccine dose within six months prior to hospitalisation, and for a sensitivity analysis, within twelve months of hospitalisation. Children who had only received one dose of vaccine and had no prior infection were excluded. We estimated VE against laboratory-confirmed SARS-CoV-2 infection separately for 1-4-year-olds and 5-17-year-olds, by conditional logistic regression stratified by calendar time (week) and adjusted for potential confounders.

Results: There were 6308 patients. The proportion of the vaccinated within six months of hospitalisation differed significantly between cases and controls in all strata of the assessed individual sociodemographic/health-related characteristics in the 5-17-year-olds, and in 1-4-year-olds who had a chronic medical condition. Overall, VE was moderate for 1-4-year-olds [41% (23-56%)] and for 5-17-year-olds [54% (10-66%)]. VE was higher in those who had received a mRNA vaccine: 87% (0-98%) and 82% (59-92%) compared with a lower VE for those who had received an inactivated vaccine: 39% (17-54%) and 30% (-19-58%), respectively for 1-4-year-olds and 5-17-year-olds although with a higher degree of imprecision in the VE for mRNA in 1-4-year-olds. In both age groups, VE was higher for those who had had no previous SARS-CoV-2 infection compared with for those who had had a previous infection.

Conclusions: SARS-CoV-2 vaccines, particularly mRNA vaccines, provided substantial protection against paediatric COVID-19-associated hospitalisations in Hong Kong during two successive SARS-CoV-2 epidemic waves dominated by the Omicron variant.

Keywords: Hong Kong; Hospitalisation; Paediatric population; SARS-CoV-2 vaccines; Test-negative design; Vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ben Cowling reports a relationship with B.J.C. has consulted for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

LinkOut - more resources